These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint. Cattaneo D; Baldelli S; Castoldi S; Charbe N; Cozzi V; Fucile S; Clementi E AIDS; 2014 Oct; 28(16):2477-80. PubMed ID: 25392858 [TBL] [Abstract][Full Text] [Related]
30. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183 [TBL] [Abstract][Full Text] [Related]
31. Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs. Chan DJ; Ray JE; McNally L; Batterham M; Smith DE Curr HIV Res; 2008 Sep; 6(5):477-84. PubMed ID: 18855660 [TBL] [Abstract][Full Text] [Related]
32. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541 [TBL] [Abstract][Full Text] [Related]
33. Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement. Mehling M; Drechsler H; Kuhle J; Hardmeier M; Doerries R; Ruegg S; Gass A J Neurovirol; 2008 Jan; 14(1):78-84. PubMed ID: 18300078 [TBL] [Abstract][Full Text] [Related]
34. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583 [TBL] [Abstract][Full Text] [Related]
35. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Puls RL; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe C; Belloso WH; Molina JM; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S; Clin Infect Dis; 2010 Oct; 51(7):855-64. PubMed ID: 20735258 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190 [TBL] [Abstract][Full Text] [Related]
37. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States. Mukerji SS; Misra V; Lorenz DR; Uno H; Morgello S; Franklin D; Ellis RJ; Letendre S; Gabuzda D Clin Infect Dis; 2018 Sep; 67(8):1182-1190. PubMed ID: 29617912 [TBL] [Abstract][Full Text] [Related]
38. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406 [TBL] [Abstract][Full Text] [Related]
39. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy. Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C; Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377 [TBL] [Abstract][Full Text] [Related]
40. Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy. Kahlert C; Bregenzer A; Gutmann C; Otterbech S; Hoffmann M; Schmid P; Vernazza P Infection; 2016 Jun; 44(3):329-35. PubMed ID: 26661659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]